## CORRECTION Open Access



## Correction: Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysis

Amand F. Schmidt<sup>1,2,3,4\*</sup>, Michael H. Davidson<sup>5,6</sup>, Marc Ditmarsch<sup>6</sup>, John J. Kastelein<sup>6,7</sup> and Chris Finan<sup>1,2,4</sup>

Correction: Alz Res Therapy 16, 228 (2024) https://doi.org/10.1186/s13195-024-01594-6

Following publication of the original article [1], an important textual error was noticed and corrected in the fourth paragraph of Background section.

The current wording erroneously states that CETP inhibitors decreases Apo-E concentration:

However, all CETP inhibitors, including the novel

The online version of the original article can be found at https://doi.org/10.1186/s13195-024-01594-6.

\*Correspondence: Amand F. Schmidt

amand.schmidt@ucl.ac.uk

<sup>1</sup>Institute of Cardiovascular Science, Faculty of Population Health, University College London, 69-75 Chenies Mews, London WC1E 6HX, UK <sup>2</sup>UCL British Heart Foundation Research Accelerator, 69-75 Chenies Mews, London WC1E 6HX, UK

<sup>3</sup>Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam UMC, locatie AMC Postbus 22660, Amsterdam Zuidoost 1100 DD, The Netherlands

<sup>4</sup>Department of Cardiology, Division Heart and Lungs, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, Utrecht 3584 CX, The Netherlands

<sup>5</sup>Pritzker School of Medicine, University of Chicago, 5801 S Ellis Ave, Chicago, IL 60637, USA

<sup>6</sup>NewAmsterdam Pharma B.V, Gooimeer 2-35, Naarden 1411 DC. Netherlands

<sup>7</sup>Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam UMC, locatie AMC Postbus 22660, Amsterdam Zuidoost 1100 DD, The Netherlands CETP-inhibitor obicetrapib, lowers plasma concentrations of apolipoprotein-E (Apo-E) [4] which is a known risk factor for dementia, in particular for Alzheimer's disease (AD).

Whereas the cited reference [4] actually shows an increasing effect. The correct wording should read:

However, all CETP inhibitors, including the novel CETP-inhibitor obicetrapib, increase plasma concentrations of apolipoprotein-E (Apo-E) [4], which is associated with decreased risk of dementia, in particular for Alzheimer's disease (AD).

The original article [1] has been updated.

Published online: 27 December 2024

## References

 Schmidt AF, Davidson MH, Ditmarsch M, et al. Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a mendelian randomization analysis. Alz Res Therapy. 2024;16:228. https://doi.org/10.1186/s1319 5-024-01594-6.

## Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.